SCOTTSDALE, Ariz., Aug. 21, 2024 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation’s largest providers of outpatient mental health care, today announced that management will present at the upcoming 22nd Annual Morgan Stanley Global Healthcare Conference, which will be hosted in New York City, NY.
Details of the presentation are as follows:
Presenters: Dave Bourdon, CFO
Date: Wednesday, September 4, 2023
Time: 10:00 a.m. (Eastern time)
Moderated by: Craig Hettenbach
The presentation will be webcast live and will be available on the Events and Presentations section of the LifeStance Health Investor Relations website (https://investor.lifestance.com).
A replay of the webcast will be available after the conclusion of the event and can be accessed on the LifeStance Health Investor Relations website.
About LifeStance Health
Founded in 2017, LifeStance (NASDAQ: LFST) is reimagining mental health. We are one of the nation’s largest providers of virtual and in-person outpatient mental health care for children, adolescents and adults experiencing a variety of mental health conditions. Our mission is to help people lead healthier, more fulfilling lives by improving access to trusted, affordable and personalized mental health care. LifeStance and its supported practices employ nearly 7,000 psychiatrists, advanced practice nurses, psychologists and therapists and operate across 33 states and more than 550 centers. To learn more, please visit www.LifeStance.com.
| Last Trade: | US$5.16 |
| Daily Change: | 0.12 2.38 |
| Daily Volume: | 1,499,737 |
| Market Cap: | US$2.010B |
August 26, 2025 August 07, 2025 May 07, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
